Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2025 · 10-Q
Revenue$115.46M$115.46M+122.8% vs Q3 2024 Net Income$117.27M$117.27MN/M vs Q3 2024 EPS Diluted$5.68$5.68N/M vs Q3 2024 Operating Income$54,931,000+1,647.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$13,075,000−63.6% Margins · derivedOperating margin47.6%+41.5 pt vs Q3 2024
Net margin101.6%+115.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 7, 2025 · 38 d after period end